TOVX - therivabio.com Price to Earnings Adjusted for Growth Rate

Corporate company logo of Theriva Biologics, Inc. (TOVX)

Theriva Biologics, Inc. (TOVX) relies on the non-cyclical biotech sector, where science rather than economics determines success. However, geopolitical tensions complicate the cross-border exchange of biomaterials. The company is currently deploying its available capital toward R&D development. The P/E to growth multiple trend confirms these data, with 0.00 serving as the current metric level, signaling the market valuation of the business dynamics.

TOVX: Synthetic Biologics PEG Multiple 04/28/2023 - 11/17/2026

Metric breakdowns and analytics for Theriva Biologics Inc (TOVX)

- market value and analyst target forecast:
Summary company analytics:TOVX Theriva Corp
Original product of Theriva Biologics

For the biotech business of Theriva Biologics, Inc. (TOVX), which focuses on oncolytic viruses, this indicator allows for the correlation of market value with profit dynamics, mitigating the risks associated with a narrow pipeline specialization. The metric is calculated by dividing the P/E ratio by the EPS growth rate, where a value below one signals a fundamental undervaluation of the asset. By analyzing the growth-normalized P/E, an investor can distinguish temporary volatility from the company's actual expansion potential.

Competitors of Theriva Biologics, Inc.

ImmunityBio, Inc. (IBRX) - Price to Net Income Growth Ratio|Immunocore Holdings - Price/Earnings to Growth Multiple|Janux Therapeutics, Inc. (JANX) - Price to Earnings Adjusted for Growth Rate|RCUS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ZYME (Zymeworks)|TNGX: PEG Multiple|IOVA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio immatics.com|Price/Earnings to Growth Multiple xencor.com (XNCR)|Price/Earnings to Growth Ratio Compass Therapeutics Inc (CMPX)|Price/Earnings to Growth Multiple Replimune Corp REPL|Lyell - Price/Earnings to Growth Multiple|PEG Multiple Innate Pharma S.A IPHA|PYXS - Price/Earnings to Growth Ratio|CGEN (Compugen) - Growth-Adjusted P/E Ratio|IO Biotech Inc. (IOBT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Sutro Bio (STRO)|Price/Earnings to Growth Multiple INKT|HOWL - Price to Net Income Growth Ratio|Price/Earnings to Growth Multiple IMMX (Immix Biopharma, Inc.)|Company Value to Earnings Growth Ratio ALXO|PEG Multiple CUE (Cue Biopharma Inc.)|Growth-Adjusted Payback Ratio PDSB|Sonnet BioTherapeutics Holdings Inc. - PEG Multiple|Price to Earnings Adjusted for Growth Rate MAIA Bio|Liminatus Pharma (LIMN) - Price/Earnings to Growth Ratio|LAVA Therapeutics NV - Growth-Adjusted Payback Ratio|NXTC (nextcure.com) - PEG Multiple|PEG Multiple leaptx.com|Price/Earnings to Growth Ratio intensitytherapeutics.com (INTS)|SNSE: Market Cap to Earnings and Growth Ratio|Gritstone bio - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income kinetabio.com (KA)|NEXI - Price/Earnings to Growth Ratio|Turnstone Biologics Corp - Company Value to Earnings Growth Ratio|VCNX: PEG Multiple|Harpoon Therapeutics Corp (HARP) - PEG Multiple